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Autologous adipose-derived stromal cell 
treatment for patients with refractory angina 
(MyStromalCell Trial): 3-years follow-up results
Abbas Ali Qayyum1* , Anders Bruun Mathiasen1, Steffen Helqvist1, Erik Jørgensen2, 
Mandana Haack‑Sørensen3, Annette Ekblond3 and Jens Kastrup1,3
Abstract 
Background: Stem cell therapy is investigated as a treatment option for patients with ischemic heart disease. In this 
study, long‑term safety and efficacy of autologous intra‑myocardial injections of adipose‑derived stromal cells (ASCs) 
was studied in patients with refractory angina.
Methods: Sixty patients with coronary artery stenosis and preserved left ventricular ejection fraction were 2:1 ran‑
domised to intramyocardial injections of ASCs or saline and followed for 3 years.
Results: For patients in the ASC group, the bicycle exercise time and the exercise performance in watt were un‑
changed (383 ± 30 s to 370 ± 44 s, P = 0.052 and 81 ± 6 to 78 ± 10, P = 0.123, respectively), but the performance 
in METs was reduced significantly (4.2 ± 0.3 to 4.0 ± 0.4, P = 0.027) during the follow‑up period. However, in the 
same period, there was in the placebo group a significant decline in bicycle exercise time (437 ± 53 s to 383 ± 58 s, 
P = 0.001), the exercise performance measured in watt (87 ± 12 W to 80 ± 12 W, P = 0.019) and in METs (4.5 ± 0.4 to 
4.1 ± 0.4, P = 0.002). Moreover, angina measured as CCS class was significantly reduced in the ASC group but not in 
the placebo group (2.5 ± 0.9 to 1.8 ± 1.2, P = 0.002 and 2.5 ± 0.8 to 2.1 ± 1.3, P = 0.186, respectively). However, no 
significant change was observed between the two groups.
Conclusions: Patients receiving ASCs had improved cardiac symptoms and unchanged exercise capacity, in opposi‑
tion to deterioration in the placebo group.
Trial registration ClinicalTrials.gov Identifier: NCT01449032. Registered 7 October 2011—Retrospectively registered, https ://
www.clini caltr ials.gov/ct2/show/NCT01 44903 2?term=jens+kastr up&rank=7
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Background
One of the leading reasons for death worldwide is related 
to ischemic heart disease [1]. Improvements in medi-
cal and interventional therapies have made the disease a 
chronic illness for a lot of patients [2]. Even though, the 
patients are not suffering from cardiac symptoms, the 
disease is in progress and it is a matter of time before 
patients develop cardiac symptoms and cardiac events. 
Atherosclerosis in coronary arteries initially results in 
asymptomatic left ventricle dysfunction, which reduces 
cardiac output leading to left ventricle overload and dila-
tation, and over time it leads to symptomatic left ventric-
ular dysfunction due to ischemia, apoptosis or necrosis. 
The symptoms related to ischemic myocardium can be 
reduced using anti-anginal medical or invasive therapies 
but the underlying disease does not disappear. Stem cell 
therapy can potentially regenerate ischemic myocardium 
and is investigated for that purpose in clinical trials. One 
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of the promising cell sources is adipose-derived stromal 
cells (ASCs), which can be obtained easily from adipose 
tissue on the abdomen and is comparable to the bone 
marrow derived mesenchymal stromal cells (MSCs) 
[3–7].
Previously, a few studies have used autologous adipose 
derived cells for patients with ischemic heart disease, but 
these cells were freshly harvested non-culture expanded 
cells [8–10]. Thus, a limited non-homogenous cell popu-
lation was given to each patient. Ex vivo culture expan-
sion of ASCs gives the opportunity to deliver a more 
homogenous and a larger amount of autologous cells to 
each patient. The anti-apoptotic effect and angiogenesis 
mediated by ASCs have preclinical been suggested to be 
related to cytokines such as IGF-I and VEGF [11, 12]. In a 
porcine model of acute myocardial infarction, intracoro-
nary administration of freshly harvested ASCs showed a 
significant reduced size of myocardial perfusion defect 
compared to the control group [13].
We assessed the safety and efficacy of intra-myocardial 
delivered vascular endothelial growth factor (VEGF-
A165) stimulated culture expanded ASCs in patients with 
chronic ischemic heart disease (CIHD) and refractory 
angina in a double-blinded placebo-controlled clinical 
study (MyStromalCell trial) [14]. After 6  months, ASC 
treatment was considered safe and the primary endpoint 
bicycle exercise capacity increased significantly in the 
ASC treated group which was not the case for patients 
who received intramyocardial injections of saline [15].
With this, the final 3  years follow-up results from 
MyStromalCell trial will be presented. These results are 
the first long-term data on intramyocardial delivered 
ASCs in patients with CIHD and refractory angina.
Methods
Study overview
MyStromalCell trial is a single-center phase II, double-
blinded, placebo-controlled study investigating the safety 
and efficacy of intra-myocardial injections of autologous 
ASCs in patients with CIHD and refractory angina.
The study protocol was approved by the Danish 
National Ethical Committee (02-268856) and Danish 
Medicines Agency (2612–2867), and complied with the 
Declaration of Helsinki. The study is registered in Clini-
calTrials.gov (NCT01449032). The Good Clinical Prac-
tice Unit of the Capital Region, Denmark monitored the 
trial throughout the 3  years study period. All patients 
received oral and written information about the study 
and signed a written informed consent prior to inclusion.
Patient population
In total, 60 patients were enrolled aged 30–80 years old 
with left ventricular ejection fraction (LVEF) > 40% and 
≥ 1 significantly coronary artery stenosis not amena-
ble for revascularization. The decision was made by the 
Heart team, which consisted of study unrelated persons. 
Despite optimal anti-anginal therapy, the patients had 
significant heart symptoms.
Inclusion and exclusion criteria are described in 
Table  1. The patients were randomized 2:1 to ASC or 
saline injections.
After intramyocardial delivery of saline or ASCs, the 
patients were followed 1, 3, 6, 12, 24 and 36 months after 
the injections (Fig. 1).
Cell preparation and culturing
In local anesthesia, approximately 100 ml of subcutane-
ous adipose tissue was obtained from the abdomen of 
each patient. Isolation and expansion of ASCs has been 
published previously [14, 15]. Briefly, the lipo-aspirate 
was washed with phosphate-buffered saline and the adi-
pose tissue was digested by collagenase NB6, neutralized 
with complete medium containing Dulbecco’s Modified 
Eagle’s Medium low glucose 1  g/l, 1% Penicillin/Strep-
tomycin (10,000  U/ml and 10.000  μg/ml, respectively) 
and 10% Fetal Bovine Serum (FBS). Then the suspension 
was filtered, centrifuged, and re-suspended in complete 
medium [16]. The isolated stromal vascular fraction was 
seeded in 75T culture flasks. Every 3–4  days, the com-
plete medium was changed, and the culture was passaged 
at 80–90% confluence. The ASCs were cultured in serum 
reduced VEGF-A165 medium for 7  days prior to the 
intramyocardial injections. Each patient was treated with 
the total amount of cells reached after 2 passages.
Electromechanical mapping and intramyocardial injection 
of ASCs
A 3D electromechanical map of left ventricle was created 
using  NOGA® system (Biologics Delivery Systems, CA, 
US). An 8-french NOGA  Myostar® injection catheter 
was used to deliver 10–15 injections of 0.2 ml of ASCs or 
saline into the ischemic region of the left ventricle.
Endpoints
Along with clinical examination, registration of side 
effects, the patients performed bicycle exercise test at 
baseline, 3, 6, 12, 24 and 36 months after injections. The 
efficacy endpoints included changes in Canadian Cardio-
vascular Society (CCS) and New York Heart Association 
(NYHA) classification, Seattle Angina Questionnaire, 
weekly use of nitroglycerin and weekly frequency of 
angina attacks. Moreover, 1  month after ASC/saline 
injections, the patients were clinically examined without 
performing bicycle exercise test.
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Statistical analysis
All statistical analysis was performed using SPSS ver-
sion 23.0 (SPSS Inc., Chicago, Illinois). Continuous 
variables are presented as mean ± standard deviation 
(SD) or 95% confidence interval and categorical vari-
ables are presented as numbers and percentages. Paired 
t-test is used for comparison of continuous data within 
groups while unpaired t-test is used for comparison 
between groups. Repeated measure with autoregressive 
covariance structure is used for follow-up data with 
more than two time-points (bicycle exercise data, 
symptoms, angina attacks, use of short-term nitro-
glycerin and Seattle Angina Questionnaire). The data 
were analyzed as intention-to-treat analysis with miss-
ing data filled in with last observation carried forward. 
Categorical data were compared using Fisher’s exact or 
Chi-square test. A two-sided P-value of < 0.05 was con-
sidered statistically significant.
Table 1 Inclusion and exclusion criteria
CABG coronary artery bypass grafting, CCS Canadian Cardiovascular Society, CT computed tomography, MRI magnetic resonance imaging, NYHA New York Heart 
Association, PCI percutaneous coronary intervention, SPECT single-photon emission computed tomography, ACS acute coronary syndrome, COPD chronic obstructive 
pulmonary disease, ETT exercise tolerance test, FEV1 forced expiratory volume in 1 s, TIA transient ischemic attack
Inclusion criteria
 Age between 30 and 80 years
 Moderate to severe angina (CCS Angina Class II–III) or angina equivalent dyspnea (NYHA class II–III) despite optimal medical therapy
 Must have, within 12 months prior to entry, documented coronary angiographic evidence of significant vessel disease, and at least one remaining 
larger coronary vessel from which new collaterals/vessels could be supplied
 Must not be eligible for any other re‑vascularization procedures
 Left ventricular ejection fraction > 40% measured by echocardiography, SPECT, CT‑scan, or MRI
 Duration of bicycle ergometry exercise tolerance tests: 2 to 10 min
 CABG or PCI within 6 months of entry must have angiography performed at least 4 months after the previous intervention to rule out early restenosis 
and to document remaining significant vessel disease
 Ventricular wall thickness of the treatment zone > 7 mm measured by echocardiography, CT‑scan, or MRI
Exclusion criteria
 Pregnant or lactating women
 Clinically significant anemia, leukopenia, leukocytosis, or thrombocytopenia
 Conditions other than angina that will limit exercise test (e.g. severe peripheral vascular disease, COPD;  FEV1 < 1)
 Immunocompromised status or currently receiving immunosuppressive therapy
 Valvular heart disease requiring surgical intervention
 Less than 6 weeks prior to screening: ACS with increase in CK‑MB or Troponins/PCI/CABG/Stroke or TIA
 History of malignancy < 5 years (except cured non‑melanoma skin cancer) or suspicion of current malignancy
 Other experimental medications within the last 4 weeks prior to the baseline ETT
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Fig. 1 Study design
Page 4 of 9Qayyum et al. J Transl Med          (2019) 17:360 
Results
Forty patients were randomly allocated to the ASC group 
and treated with 72 ± 45 × 106 ASCs culture expanded 
for 32 ± 14 days. The injection volume with the expanded 
ASCs was 3 ml. The cell viability was 89 ± 5%. No signs of 
contamination with bacteria, yeast or mycoplasma were 
detected. Remaining 20 patients received intramyocar-
dial saline injections. Baseline characteristics and medi-
cine are shown in Table 2 and 3, respectively.
Safety
During the 3  years follow-up, 4 patients died. Death of 
three patients was attributed to a cardiovascular event 
while 1 of the patient died due to meningioma. One 
patient died prior to 1-month examination, the other 
patients died 34, 35 and 36  months after treatment, 
respectively.
During follow-up time, 4 patients developed cancer. 
One patient from ASC group developed meningioma. 
The patients in the placebo group developed prostate 
cancer, stomach cancer and myeloid leukemia (Table 4).
Six patients did not show up for 36 months follow-up. 
Four of them were not alive, 1 had stomach cancer and 
was not able to show up and 1 patient had upper airway 
infection.
Exercise tolerance testing
At 3  years follow-up, the mean bicycle exercise tol-
erance time was un-changed in the ASC group from 
383 ± 30  s to 370 ± 44  s (P = 0.052), while it decreased 
significantly in the placebo group from 437 ± 53  s to 
383 ± 58  s (P = 0.001) (Fig.  2). A significant decrease 
was also observed in the placebo group for the perfor-
mance expressed in watt from 87 ± 12  W at baseline to 
80 ± 12  W (P = 0.019), but was un-changed in patients 
treated with ASCs from baseline to 3  years follow-up 
(81 ± 6 W to 78 ± 10 W, P = 0.123).
Corresponding metabolic equivalents (METs) was 
reduced significantly in both the ASC group (from 
4.2 ± 0.3 to 4.0 ± 0.4, P = 0.027) and in the placebo group 
(from 4.5 ± 0.4 to 4.1 ± 0.4, P = 0.002) during the 3 years 
follow-up period.
There were no significant differences between groups 
during the 3 years of follow-up (Table 5).
Table 2 Baseline characteristics
AMI acute myocardial infarction, ASC adipose-derived stromal cell, BMI body 
mass index, CABG coronary artery bypass grafting, LVEF left ventricular ejection 
fraction, n number of patients, PCI percutaneous coronary intervention
Parameter Placebo (n = 20) ASC (n = 40) P-value
Age (years) 65.3 ± 8.7 65.5 ± 9.7 0.94
Male gender 20 (100) 35 (87.5) 0.02
BMI (kg/m2) 30.0 ± 4.8 30.0 ± 4.1 0.92
Smoking 0.19
 Current 3 (15) 8 (20)
 Previous 16 (80) 23 (57.5)
 Never 1 (5) 9 (22.5)
Diabetes mellitus 6 (30) 16 (40) 0.57
Hypertension 12 (60) 33 (82.5) 0.06
Previous AMI 10 (50) 26 (65) 0.26
Previous CABG 20 (100) 33 (82.5) 0.08
Previous PCI 15 (75) 28 (70) 0.69
LVEF (%) 54 ± 8 52 ± 8 0.38
Table 3 Baseline medication
ACE-I angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor 
blockers, ASC adipose-derived stromal cell, n number of patients
Medication Placebo (n = 20) ASC (n = 40) P-value
Acetylsalicylic acid 19 (95) 35 (87.5) 0.65
Clopidogrel 7 (35) 11 (27.5) 0.56
ACE‑I or ARB 13 (65) 29 (72.5) 0.42
β‑blocker 16 (80) 33 (82.5) 1.00
Calcium antagonist 12 (60) 19 (47.5) 0.42
Diuretics 12 (60) 27 (67.5) 0.58
Statins 20 (100) 40 (100) 1.00
Nitrate 19 (95) 28 (70) 0.04
Nicorandil 6 (30) 5 (12.5) 0.16
Ivabradine 2 (10) 4 (10) 1.00
Table 4 Serious adverse events during  3  years follow-up 
in  the  placebo and  adipose-derived stromal cell (ASC) 
group
Values are n (%); P values are calculated using Fischer’s exact test except for 
angina worsening, which is calculated using Chi-square test
PCI percutaneous coronary intervention, TIA transient ischemic attack
Serious adverse events Placebo (n = 20) ASC (n = 40) P-value
Death 0 (0) 4 (10) 0.291
Hospitalizations
 Myocardial infarction 5 (25) 8 (20) 0.744
 Dyspnea 0 (0) 1 (2.5) 1.000
 Anemia 2 (10) 3 (7.5) 1.000
 Syncope 1 (5) 0 (0) 0.333
 Peripheral edema 0 (0) 1 (2.5) 1.000
 Angina worsening 12 (60) 14 (35) 0.028
 Pneumonia 1 (5) 4 (10) 0.656
 PCI 7 (35) 6 (15) 0.101
 Heart failure 0 (0) 4 (10) 0.291
 TIA/apoplexia cerebri 2 (10) 0 (0) 0.107
 Pulmonary embolism 0 (0) 1 (5) 1.000
 Cancer 3 (15) 1 (5) 0.103
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Cardiac symptoms and anti-anginal medication
During the 3  years follow-up period, significant 
decreased angina was observed measured as CCS classifi-
cation in the ASC group (2.5 ± 0.9 to 1.8 ± 1.2, P = 0.002) 
while the symptoms were unchanged the placebo group 
(2.5 ± 0.8 to 2.1 ± 1.3, P = 0.186) (Fig. 3).
The chest discomfort was significantly reduced in 
the placebo group during the period from baseline to 
6 months follow-up but then increased again while the 
CCS classification was significantly reduced for patients 
in ASC group from baseline to 6 months follow-up and 
remained decreased during the entire follow-up period 
(Fig. 3).
For NYHA classification, there was a significant 
reduction observed in the ASC group (2.4 ± 0.6 to 
2.2 ± 0.8, P = 0.007) while there was no significant 
change in the placebo group (2.7 ± 0.6 to 2.4 ± 0.8, 
P = 0.314).
The patients reported significantly reduced number 
of weekly angina attacks in the ASC group (P = 0.017) 
Fig. 2 Bicycle exercise test. Performance in a time duration, b in watt and c in METs
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while this number was unchanged in the placebo group 
(P = 0.425).
In the same period, the use of short-term nitroglyc-
erin was unchanged in both groups (ASC: P = 0.176 
and Placebo: P = 0.123).
Seattle Angina Questionnaire
Significant improved quality-of-life (P < 0.001 and 
P = 0.045 for ASC and placebo group, respectively), 
angina stability (P < 0.001 and P = 0.003 for ASC and pla-
cebo group, respectively), angina frequency (P < 0.001 
Table 5 Bicycle exercise test. Difference between groups
Follow-up time Group Mean difference 
from baseline
Standard 
deviation
Mean difference 
between groups
95% Confidence interval 
of the difference
P-value
Lower Upper
Time 12 months Placebo 10 118 34 − 29 97 0.288
ASC − 24 113
24 months Placebo 24 98 37 − 25 100 0.239
ASC − 13 121
36 months Placebo 51 100 39 − 13 91 0.141
ASC 12 92
Watt 12 months Placebo − 4.4 24.2 0.4 − 12.3 13.1 0.952
ASC − 4.7 22.7
24 months Placebo 1.0 23.0 4.3 − 9.4 18.1 0.529
ASC − 3.3 25.9
36 months Placebo 6.6 23.4 4.0 − 7.5 15.5 0.488
ASC 2.6 19.6
Mets 12 months Placebo 0.07 1.00 0.28 − 0.23 0.78 0.277
ASC − 0.21 0.88
24 months Placebo 0.17 0.88 0.23 − 0.27 0.74 0.355
ASC − 0.07 0.93
36 months Placebo 0.41 0.86 0.27 − 0.16 0.69 0.212
ASC 0.14 0.72
Fig. 3 Cardiac symptoms measured as a CCS classification and b NYHA classification
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and P = 0.012 for ASC and placebo group, respectively) 
and physical limitation score (P = 0.002 and P = 0.017 
for ASC and placebo group, respectively) was observed 
in both groups but no significant change in overall sat-
isfaction score was seen in any of the groups (P = 0.489 
and P = 0.604 for ASC and placebo group, respectively). 
There were no differences in any parameter between the 
two groups.
Discussion
The present study is reporting long-term safety and effi-
cacy data for the first in man randomized, double-blinded 
placebo-controlled study using VEGF-A165 stimulated 
culture expanded ASCs for patients with refractory 
angina.
The bicycle exercise performance decreased signifi-
cantly in the placebo group but was unchanged in the 
ASC group except for the performance measured in 
METs at 3 years follow-up.
Cardiac symptoms measured as CCS class and the 
numbers of weekly angina attacks were significantly 
reduced during the 3  years of follow-up time for the 
patients treated with ASCs while there were no changes 
for the patients receiving saline injections. However, 
use of short-term nitroglycerin was un-changed in both 
groups.
For patients in both groups, significant improved qual-
ity-of-life, angina stability, angina frequency and physical 
limitation score was observed.
Chronic ischemic heart disease is a progressive dis-
ease. During the follow-up period of 3 years, 13 patients 
were admitted due to acute myocardial infarction and 26 
due to angina worsening. The decrease in bicycle perfor-
mance in the placebo group illustrates the progressive 
nature of coronary artery disease.
Interestingly, during the first 6  months follow-up 
period, significant improvement in heart symptoms of all 
patients was seen. However, the present long-term data 
demonstrated that patients allocated into the saline group 
returned to baseline cardiac symptoms but for patients in 
the ASC group, the heart symptoms remained decreased 
during the entire follow-up period. Along with this, the 
number of weekly angina attacks was only reduced in the 
ASC group. It can be speculated whether this effect over 
time in reduced cardiac symptoms would have been seen 
if only growth factors were injected. However, injection 
of growth factors may result in rapid dilution while ASCs 
are bigger in size and may stay in the injected tissue for 
a time period. Moreover, ASCs may secrete a cocktail of 
growth factors in a highly complex manner to promote 
angiogenesis. Nevertheless, for the patients it is highly 
important that any type of treatment results in decreased 
morbidity and mortality.
Previous published studies using exercise test as an 
outcome measure, show similar change in exercise 
capacity after  CD34+ injections in patients with chronic 
ischemic heart disease and refractory angina [17–19]. In 
these studies, the patients received a standardized dose of 
cells. In the present study, the patients received the total 
amount of cells reached after two cell culture expansion 
passages and thus there were a patient-to-patient varia-
tion in the number of cells delivered.
Intra-myocardial injection of freshly harvested adipose-
derived cells have been used in patients with refractory 
angina, which showed that exercise capacity measured as 
METs in the cell group remained stable while there was a 
decrease in METs in the placebo group [9]. It is the same 
tendency as in our study.
Another study also using freshly harvested autolo-
gous adipose derived cells injected intramyocardially in 
patients with ischemic heart failure showed increased 
maximum oxygen consumption on exercise treadmill in 
patients receiving cells but did not differed significantly 
from the placebo group [8].
Another small study delivering freshly harvested adi-
pose-derived cells intracoronary in patients with ST-
elevations myocardial infarction showed a trend towards 
improved LVEF [10].
Previously at our center, we have conducted studies 
using autologous bone marrow derived mesenchymal 
stromal cells for patients with chronic ischemic heart 
disease with and without heart failure [20–22]. These 
studies have demonstrated improvement in patients self-
reported health, increase in LVEF, decreased left ven-
tricular end-systolic volume and reduced amount of scar 
tissue.
It has been increasingly clear for many research groups, 
that the expansion of autologous cells in flasks makes it 
very difficult to deliver a standardized stem cell treat-
ment. New cell culture methods using bioreactor sys-
tems to reach a standardized cell count for allogeneic 
treatments are now available for clinical use [23]. These 
systems have been used in a phase I trial, to produce an 
allogeneic cell product (CSCC_ASC) comparable to the 
one used in this trial as autologous product, for treat-
ment in 10 patients with ischemic heart failure [24]. The 
aim was to investigate the safety of intra-myocardial 
injections of 100 million ASCs from healthy donors. No 
treatment-related side effects were observed.
Furthermore, CSCC_ASC is being tested in a Dan-
ish and European multicentre double-blinded placebo-
controlled trial for treatment of patients with ischemic 
heart failure (EudraCT: 2015-001560-19 and EudraCT: 
2015-002929-19, respectively) [25, 26].
Moreover, a single-centre study initiated Janu-
ary 2019 is investigating CSCC_ASC in patients 
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with non-ischemic heart failure (EudraCT: 
2018-002538-19).
In this study, the total amount of ASCs reached 
were injected into the patients allocated to the active 
therapy group, while the adipose tissue obtained 
from some of the patients in the placebo group, were 
used for characterization of ASCs [16]. Gene expres-
sion levels by quantitative real-time PCR analysis of 
ASCs showed that transcription of endothelial mark-
ers FOXF1, vWF, and VEGFR1 were up-regulated. By 
flow cytometry, we found the characteristic mesenchy-
mal stem cell markers CD13, CD73, CD90, and CD105 
on ASCs and they were lacking HLA-DR, CD19, and 
CD14.
So, the accumulated experience from clinical stem 
cell trials, the established safety and efficacy data 
has led this field to move from autologous to alloge-
neic therapy, reducing the logistical obstacles meet in 
previous studies. Furthermore, this field moves on to 
give a standardized amount of cell therapy safely and 
equally to all patients. However, as it is known from 
traditional pharmaceutical therapies, mostly repeated 
treatment is used. It may be of interest to investigate 
the role of cell therapy with two treatments within a 
short period.
The obvious benefit of cell therapy may be that it has 
the potential to regenerate the ischemic myocardium 
compared to conventional medical and interventional 
therapies. However, we did not have long term imag-
ing modalities to detect changes in myocardial perfu-
sion [27]. Moreover, in a selected group of patients the 
yield of cells and the effect of therapy may be higher 
[28]. Even though, this study is a randomized clinical 
trial, there were only male in the placebo group and a 
trend towards significant difference between the two 
groups for hypertension and previous coronary artery 
bypass grafting. Thus, these factors could potential be 
confounders.
Even though, the primary end-point did not differ 
between the two groups at 6  months follow-up, there 
was at 6  months follow-up a significant increase in 
bicycle exercise capacity in the ASC group, which was 
not the case for patients in the placebo group.
Probably, a larger amount of patients were needed 
in this study to detect a significant difference between 
groups for the primary end point. However, reduced 
cardiac symptoms are essential for the patient’s quality 
of life, which was seen only for the patients in the ASC 
group in this long-term follow-up period.
Conclusion
In conclusion, patients receiving ASC injections, in 
this double-blinded placebo-controlled study, had pre-
served exercise capacity, while patients in the placebo 
group experienced significantly reduced exercise per-
formance. Additionally, patients receiving ASCs had 
significantly improved cardiac symptoms, which was 
not the case for patients allocated in the placebo group.
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